Testing a new vitamin supplement for ulcerative colitis

Plain-English translation of NCT06488625 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a medication called CICR-NAM, a specially designed form of nicotinamide (a B vitamin), to see if it can help treat ulcerative colitis. Researchers want to find out whether this medication can reduce inflammation and improve symptoms in people with mild to moderate disease activity. You would take either the medication at one of two doses or a placebo (a dummy pill with no active ingredient) for up to one year.

Current treatments for ulcerative colitis don't work well enough for everyone, and some people experience side effects. This trial is exploring whether this medication might offer a new, safer option to help control symptoms and allow the gut to heal.

Do you qualify?

You likely qualify if…

you have been diagnosed with ulcerative colitis for at least 3 months and have had at least one flare-up in the past year
you have mild to moderate disease activity at the time you join the study
you are between 18 and 80 years old
you have had a recent colonoscopy (within one year) with no signs of cancer
you have blood tests showing elevated inflammation markers (CRP or fecal calprotectin)
you are able to understand the study requirements and give written informed consent

You likely don't qualify if…

you have severe ulcerative colitis or very high inflammation markers
you have been diagnosed with Crohn's disease or other types of colitis
you have had bowel surgery before (except appendix removal) or have strictures causing blockage
you have a current infection in your gut or positive tests for infection at screening
you have a history of colon cancer, high-grade dysplasia, or other cancers (except skin cancer that has been completely removed)

What participation looks like

You would visit the study clinic for screening tests, including blood work and a colonoscopy to confirm your diagnosis and measure inflammation. If you qualify, you would take 6 tablets by mouth every day for 52 weeks total—12 weeks of an initial treatment phase followed by 40 weeks of maintenance. Some tablets would contain the active medication and some would be placebo (you won't know which), and you would have regular follow-up visits to check how you're doing and monitor for any side effects.

AI-generated summary from trial data · Jun 11, 2026 · Not medical advice

Trial locations(26 sites)

Germany

Universitaetsklinikum Schleswig-Holstein AöR, Kiel, Schleswig-Holstein

Universitaetsklinikum Aachen AöR, Aachen

Universitaetsklinikum Augsburg, Augsburg

Sozialstiftung Bamberg, Bamberg

Charite Universitaetsmedizin Berlin KöR, Berlin